

Nanexa invites to Capital Markets Day on May 7

Nanexa AB invites investors, analysts and other stakeholders to a Capital Markets Day on Tuesday, May 7, at 1:00-3:00 pm at the Royal Swedish Academy of Engineering Sciences (IVA) in Stockholm.

At the event, Nanexa's Chairman Göran Ando, CEO David Westberg and members of the management team will provide an in-depth description of the business, focusing on the following areas:

- Status and ongoing development within Nanexa's own NEX-22 project
- Nanexa's collaboration with Novo Nordisk and other prioritized partner projects
- Status and ongoing development of Nanexa's PharmaShell system, and experience from pre-clinical and clinical studies
- The larger perspective of the GLP-1 market in type 2 diabetes and obesity
- Business development – experiences and opportunities ahead
- Focus 2024-2025 – Nanexa's plan to ensure continued growth and success

The presentations will be held in Swedish and participants will have the opportunity to ask questions directly to the speakers. For those who cannot attend, the event will be recorded and made available on the Nanexa website afterwards.

Date: Tuesday May 7, 2024

Time: 1:00-3:00 pm. Coffee will be served in connection

Place: Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm.

Registration: You are welcome to register by e-mail to maria.medeen@nanexa.se by May 3.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

The company's Certified Adviser is Carnegie Investment Bank AB (publ).

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

[Nanexa invites to Capital Markets Day on May 7](#)